Physician profile
David T Harrison
NPI 1346265436
$852.04
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2021: $484 · 2023: $19.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $139.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $130.40 | 2019-2021 | |
| Array Biopharma INC | $118.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2021 | |
| Incyte Corporation | $65.00 | 2021 | |
| Eisai INC. | $42.34 | 2021 | |
| Abbvie INC. | $41.72 | 2021-2023 | |
| Genzyme Corporation | $41.10 | 2021 | |
| Morphosys, US INC. | $22.25 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $21.37 | 2021 | |
| Astellas Pharma US INC | $21.31 | 2021 | |
| Merck Sharp & Dohme LLC | $18.76 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.06 | 2021 | |
| Lilly USA, LLC | $15.24 | 2021 | |
| Daiichi Sankyo INC. | $15.21 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.87 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.19 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.